{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ae2eea79-0436-4969-b361-3f995676a533 --><h2>Changes</h2><!-- end field ae2eea79-0436-4969-b361-3f995676a533 -->","summary":null,"htmlStringContent":"<!-- begin item 025e564a-3046-48ae-9493-bf292cb3d183 --><!-- begin field d27ad90e-3c5f-4e29-8352-e3debdf6e8a3 --><p><strong>September 2020</strong> – minor update. Adverse effects updated for thiazide-type diuretics in line with revised manufacturers' SPCs.</p><p><strong>July 2020</strong> – minor update. Typographical error corrected in the section on Prescribing information.</p><p><strong>May 2020</strong> – minor update. Prescribing information has been added in response to the National Institute for Health and Care Excellence (NICE)<em> COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19</em> to reflect the advice during the COVID-19 pandemic.</p><p><strong>October 2019</strong> — minor update. This topic has been updated to align with the National Institute for Health and Care Excellence (NICE) guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>], which updates and replaces the NICE guideline <em>Hypertension: The clinical management of primary hypertension in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">National Clinical Guideline Centre, 2011</a>]. The topic has also been restructured for clarity. </p><ul><li>NICE reviewed the evidence and made new recommendations on the following:<ul><li>Diagnosing hypertension.</li><li>Starting antihypertensive drug treatment.</li><li>Monitoring treatment and blood pressure targets.</li><li>Choosing antihypertensive drug treatment (treatment steps 1 to 4).</li><li>Who to refer for same-day specialist review.</li></ul></li><li>NICE also made some changes without an evidence review, including:<ul><li>Replacing plasma glucose testing with HbA1c to reflect current practice.</li><li>Adding a footnote to highlight concerns about the risks of salt substitutes in some groups of people.</li></ul></li></ul><p><strong>January 2018 </strong>—<strong> </strong>minor update. Revised SPC for Istin® (amlodipine) 5 and 10mg tablets. Drug interactions updated as per the revised SPC.</p><p><strong>May to June 2017 </strong>— reviewed. A literature search was conducted in May 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field d27ad90e-3c5f-4e29-8352-e3debdf6e8a3 --><!-- end item 025e564a-3046-48ae-9493-bf292cb3d183 -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"8e6bad96-1cd5-5eb3-b28b-b67489532fa2","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 1ba53b47-9f61-4f45-a5ab-2913e47cd430 --><h3>Previous changes</h3><!-- end field 1ba53b47-9f61-4f45-a5ab-2913e47cd430 -->","summary":null,"htmlStringContent":"<!-- begin item f170068f-77a1-456e-ad68-ea38cb499f5e --><!-- begin field 0829a556-b68c-43bc-b70f-21838ad63334 --><p><strong>October 2015</strong> — minor updates.</p><ul><li>The information on beta blockers in the Prescribing information section has been re-worded to reflect advice from the manufacturers' Summary of Product Characteristics, in relation to the cautions and contraindications of beta blockers if the person has a form of obstructive airways disease.</li><li>Based on an update to the Summary of Product Characteristics (SPC) for Tritace<sup>®</sup> (ramipril), other common adverse effects of angiotensin- converting enzyme (ACE) inhibitors and a drug interaction with vildagliptin have been added to the section on Prescribing information.</li><li>The recommendation on when to offer a statin to people with hypertension has been deleted and links have been provided to the CKS topics on Lipid modification - CVD prevention and CVD risk assessment and management.</li><li>The advice regarding the concurrent use of renin-angiotensin system (RAS) blocking drugs has been further clarified, based on an update to the Summary of Product Characteristics (SPC) for Tritace<sup>®</sup> (ramipril).</li></ul><p><strong>May 2015</strong> — minor updates:</p><ul><li>The Medicines and Healthcare products Regulatory Agency (MHRA) warning regarding the concurrent use of RAS drugs has been clarified.</li><li>Information about the increased risk of hyperkalaemia with concurrent use of spironolactone and nonsteroidal anti-inflammatory drugs has been updated in line with the SPC for spironolactone.</li></ul><p><strong>February 2015</strong> — minor update. Following external feedback, the text recommending that people who have a blood pressure reading of 220/120 mmHg has been removed. This is not a NICE recommendation and has therefore been removed.</p><p><strong>July 2014</strong> — minor update. Advice from the MHRA to not prescribe medicines from different classes of renin-angiotensin system blocking agents in combination (for example an angiotensin-converting enzyme [ACE] inhibitor plus an angiotensin-II receptor antagonist) has been incorporated into the topic.</p><p><strong>December 2013</strong> — minor update. Prescribing information has been updated in line with the SPC for perindopril.</p><p><strong>July 2013</strong> — minor update. Links to the DVLA website have been updated.</p><p><strong>July 2013</strong> — minor update. The management of abnormal results in people who is on an angiotensin-converting enzyme inhibitor or angiotensin-II receptor antagonist was updated according to the updated National Institute for Health and Care Excellence guideline: Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>November 2011 to January 2012</strong> — revised. A literature search was conducted in October 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. The topic also reflects new and updated recommendations in the clinical guideline Hypertension. Clinical management of primary hypertension in adults from the National Institute for Health and Care Excellence. Text changes include updates on blood pressure measurement, the use of ambulatory and home blood pressure monitoring, modified blood pressure targets, and antihypertensive drug treatments. Issued in April 2012.</p><p><strong>July 2011</strong> — minor update. Included cough as a very rare, but possible adverse effect of candesartan. This information is based on the updated Summary of Product Characteristics for Amias®. Issued in September 2011.</p><p><strong>May 2011</strong> — minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011</strong> — technical update. The management section of this topic has been simplified to improve clarity and navigation. There have been no changes to the clinical content or meaning of the recommendations.</p><p><strong>October 2010 </strong>— minor update. Information on fitness to drive from the Driver and Vehicle Licensing Agency's guidance for medical practitioners, <em>At a glance guide to the current medical standards of fitness to drive</em>, has been added. Issued in October 2010.</p><p><strong>January 2010</strong> — minor update. Advice regarding how to deal with abnormal urea and electrolyte results for people taking diuretics has been clarified. Issued in January 2010.</p><p><strong>December 2009</strong> — minor update. Text added regarding potential drug interactions between antidepressants and alpha-blockers, beta-blockers, and calcium-channel blockers, in line with NICE guidance Depression in adults with a chronic physical health problem. The recommendations on when to consider antiplatelet treatment for primary prevention of cardiovascular disease have also been updated. Issued in December 2009.</p><p><strong>October 2009 </strong>— minor update. A reminder from the Medicines and Healthcare products Regulatory Agency (MHRA) that aspirin is not licensed for use in primary prevention of vascular events has been added. Issued in October 2009.</p><p><strong>February to July 2009</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There have been no major changes to the recommendations.</p><p><strong>May 2009</strong> — minor update to include drug safety advice from the Medicines and Healthcare products Regulatory Agency on the use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor antagonists in women who are breastfeeding. Issued in June 2009.</p><p><strong>March 2009 </strong>— minor update. The Quality and Outcomes Framework (QOF) indicators for hypertension have been updated in the Goals and outcome measures section. Losartan has been reclassified as a black triangle drug by the Medicines and Healthcare products Regulatory Agency (MHRA). However, this is due to harmonisation of the Summary of Product Characteristics across the European Union, not because of any newly identified safety issues. Issued in April 2009.</p><p><strong>April 2008 </strong>— minor update to text regarding availability of the new perindopril arginine salt. Issued May 2008.</p><p><strong>January 2008 </strong>— updated. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently advised that ACE inhibitors and angiotensin II receptor antagonists should not be used at any stage of pregnancy. Issued in January 2008.</p><p><strong>July to September 2006 </strong>— reviewed. Validated in December 2006 and issued in January 2007.</p><p><strong>October 2005</strong> — minor update. Reference made to the CKS topic on Antiplatelet treatment which outlines gastrointestinal issues that need to be considered in the prescribing of low-dose aspirin for the prevention of cardiovascular events. Issued in November 2005.</p><p><strong>November 2004</strong> — reviewed to incorporate evidence-graded recommendations from the National Institute for Health and Care Excellence (NICE) 2004 guideline on Essential hypertension: managing adult patients in primary care (written by the North of England Hypertension Guideline Development Group) and the British Hypertension Society (BHS) 2004 Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 — BHS IV. Evidence from systematic reviews and meta-analyses published since the NICE and BHS guidelines were written have also been included where relevant. Validated in March 2005 and issued in July 2005.</p><p><strong>November 2002</strong> — reviewed and updated to incorporate evidence-graded recommendations from the Scottish Intercollegiate Guidelines Network (SIGN) guideline on Hypertension in Older People (2001), and evidence from more recent clinical trials. Issued in April 2003.</p><p><strong>October 2000 </strong>— updated to incorporate National Service Framework for Coronary Heart Disease (NSF for CHD) recommendations. Issued in December 2000.</p><p><strong>September 1999</strong> — written, based on the BHS 1999 guidelines on the management of hypertension. Validated in November 1999 and issued in December 1999.</p><!-- end field 0829a556-b68c-43bc-b70f-21838ad63334 --><!-- end item f170068f-77a1-456e-ad68-ea38cb499f5e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}